Related by context. All words. (Click for frequent words.) 72 leukemia ALL 72 leukemia AML 71 Chronic lymphocytic leukemia 70 Acute lymphoblastic leukemia 70 relapsed MM 70 Waldenstrom macroglobulinemia 69 Leukemias 69 heavily pretreated 69 histologic subtype 69 mycosis fungoides 69 acute myelogenous leukemia AML 69 Acute myeloid leukemia 69 CYT# potent vascular disrupting 68 acute GvHD 68 myelodysplastic syndrome MDS 68 recurrent glioblastoma multiforme 68 essential thrombocythemia 68 histologies 68 systemic lupus erythematosus 68 lymphocytic leukemia 68 basal cell carcinoma BCC 68 acute myeloid 68 histological subtype 68 Glioblastoma multiforme GBM 68 MGUS 68 hematopoietic cancers 68 MELAS 68 metastatic bladder 68 myeloproliferative neoplasms 67 metastatic renal cell carcinoma 67 leukemia CLL 67 HNSCC 67 acute promyelocytic leukemia 67 pediatric acute lymphoblastic 67 nonmelanoma skin cancers 67 juvenile idiopathic arthritis JIA 67 HIV HCV coinfected 67 medulloblastomas 67 chronic lymphocytic leukemia CLL 67 HER2 positive metastatic breast 67 nonmetastatic 67 ependymoma 66 systemic lupus erythematosus SLE 66 follicular lymphoma FL 66 Glioblastoma Multiforme 66 Hodgkin lymphoma HL 66 complement inhibitor eculizumab 66 myelofibrosis polycythemia vera 66 Follicular lymphoma 66 refractory indolent non 66 Omacetaxine 66 Gleevec resistant 66 hematologic toxicity 66 candidemia 66 astrocytomas 66 neuroendocrine tumors 66 metastatic malignant melanoma 66 lupus nephritis 66 papillary renal cell carcinoma 66 haematologic 66 HBeAg negative 66 oligodendrogliomas 66 autoantibody positive 66 carcinoid tumors 66 leukaemias 66 hepatocellular carcinoma HCC 66 sorafenib Nexavar 66 idarubicin 66 nonsmall cell lung cancer 66 invasive candidiasis 66 metastatic kidney 66 HER2 overexpression 66 smoldering myeloma 66 nasopharyngeal carcinoma 66 alveolar rhabdomyosarcoma 66 T1DM 66 SCCHN 66 pancreatic adenocarcinoma 65 Adjuvant chemotherapy 65 MALT lymphoma 65 sorafenib Nexavar ® 65 grade gliomas 65 Glioma 65 cancer mCRC 65 hematological malignancy 65 PCNSL 65 hepatorenal syndrome 65 grade cervical intraepithelial 65 allogeneic HSCT 65 basal cell nevus syndrome 65 Acute Myeloid Leukaemia AML 65 epithelial tumors 65 ADPKD 65 cell acute lymphoblastic 65 pancreatic NET 65 Severe Primary IGFD 65 myeloproliferative disorders 65 onset diabetes mellitus 65 Myelodysplastic syndromes MDS 65 chronic periodontitis 65 myelofibrosis MF 65 Cutaneous T 65 Toxicities 65 osteosarcomas 65 Annamycin 65 KRAS mutations occur 65 GISTs 65 acute lymphoblastic 65 malignant neoplasm 65 soft tissue sarcomas 65 endometrial hyperplasia 65 Wegener granulomatosis 65 Doxil ® 65 colorectal adenoma 65 juvenile idiopathic arthritis 65 MYCN amplification 65 node metastases 65 TTR amyloidosis 65 Voreloxin 65 malignant lymphomas 65 metastatic malignant 65 Chronic lymphocytic leukemia CLL 65 polyarticular 64 erlotinib Tarceva ® 64 vWD 64 fallopian tube carcinoma 64 T1c 64 paraganglioma 64 lymphoma subtypes 64 prostate carcinoma 64 Zolinza 64 neuroblastomas 64 EGFR mutation positive 64 imatinib Gleevec ® 64 juvenile myelomonocytic leukemia 64 metastatic gastric 64 metastatic renal 64 differentiated thyroid 64 metastatic lung cancer 64 Folfox 64 lymphoid malignancies 64 lymphoproliferative disorder 64 non metastatic osteosarcoma 64 medullary thyroid cancer 64 prostate cancer CaP 64 cervical carcinoma 64 Medulloblastoma 64 Lung transplantation 64 carcinoid 64 Carcinoid tumors 64 pheochromocytoma 64 indolent lymphoma 64 malignant pleural mesothelioma 64 macroglobulinemia 64 lymphoproliferative disorders 64 glioblastoma multiforme GBM 64 Gliomas 64 bone metastasis 64 metastatic colorectal 64 refractory CTCL 64 Synovial sarcoma 64 receptor tyrosine kinase inhibitor 64 Wilms tumor 64 renal cell carcinomas 64 chronic myelogenous leukemia CML 64 CMV infection 64 myelogenous leukemia 64 Surgical resection 64 gastrointestinal stromal tumor 64 relapsed leukemia 64 precancerous condition 64 Glioblastoma multiforme 64 advanced metastatic prostate 64 thymoma 64 gefitinib Iressa 64 Chronic myeloid leukemia 64 indolent NHL 64 neuroendocrine cancers 64 hepatoblastoma 64 gastric adenocarcinoma 64 Bronchiectasis 64 homozygous familial hypercholesterolemia 64 recurrent glioblastoma multiforme GBM 64 enterocolitis 64 Non Hodgkin lymphoma 64 thalidomide Thalomid 64 pomalidomide 64 SJIA 64 hematologic disorders 64 neoplasias 64 Cloretazine 64 kidney urologic 64 BRCA deficient 64 ara C 64 nonalcoholic steatohepatitis NASH 64 atypical hyperplasia 64 idiopathic thrombocytopenic purpura 64 ceroid lipofuscinosis NCL 64 myeloproliferative 64 Li Fraumeni syndrome 64 heavily pretreated patients 64 myelodysplastic syndromes 64 Systemic lupus erythematosus SLE 64 VUR 64 Osteosarcoma 63 Acute Myelogenous Leukemia 63 dasatinib Sprycel 63 cell lymphoma CTCL 63 CLL SLL 63 malignant lymphoma 63 antimetabolite 63 intraventricular hemorrhage 63 tigecycline 63 nonmelanoma skin cancer 63 recurrent glioblastoma 63 Hurthle cell 63 HER2 positive cancers 63 atypical hemolytic uremic syndrome 63 mTOR inhibitors 63 invasive aspergillosis 63 neoplasm 63 TACI Ig 63 malignant brain 63 imatinib Gleevec 63 diabetes mellitus DM 63 breast carcinomas 63 HCV infection 63 idiopathic PAH 63 SSc 63 Myelodysplastic Syndrome MDS 63 metastatic neuroendocrine tumors 63 cirrhosis liver failure 63 endometrial carcinoma 63 Sezary syndrome 63 non Hodgkin lymphomas 63 HeFH 63 Fludarabine 63 acute lymphoid leukemia 63 Diffuse Large B 63 EGFR expressing 63 Anaplastic 63 squamous cell lung cancer 63 Sudhir Agrawal D.Phil 63 hepatocellular carcinomas 63 NMIBC 63 gastrointestinal stromal 63 renal carcinoma 63 sunitinib malate 63 relapsed ovarian cancer 63 relapsed ALL 63 refractory AML 63 Endometrial cancer 63 Enzastaurin 63 chronic myeloid 63 panobinostat 63 gastrointestinal stromal tumor GIST 63 cisplatin chemotherapy 63 acute promyelocytic leukemia APL 63 Lafora disease 63 pancreatic neuroendocrine tumors 63 metastatic GIST 63 refractory NSCLC 63 superficial bladder cancer 63 recurrent malignant glioma 63 squamous cell carcinoma SCC 63 Follicular Lymphoma 63 KRAS wild 63 mRCC 63 bronchogenic carcinoma 63 cisplatin gemcitabine 63 operable breast cancer 63 cisplatin resistant 63 prognostic variables 63 cilengitide 63 hypophosphatasia 63 dysglycemia 63 tumor subtypes 63 docetaxel chemotherapy 63 TTF Therapy 63 hereditary predisposition 63 vinca alkaloid 63 refractory chronic lymphocytic 63 lenalidomide dexamethasone 63 bexarotene 63 stage IIIB 63 MGd 63 polycythemia vera PV 63 hepatocellular carcinoma 63 gastric carcinoma 63 Hepatocellular Carcinoma HCC 63 familial adenomatous polyposis 63 nasopharyngeal cancer 63 epithelial ovarian 63 cytarabine daunorubicin 63 lenalidomide Revlimid R 63 cervical intraepithelial neoplasia 63 astrocytoma 63 pilocytic astrocytoma 63 Basal cell 63 adenomatous polyps 63 brain metastases 62 Talabostat 62 Vidaza azacitidine 62 galiximab 62 lymphoblastic leukemia 62 taxane chemotherapy 62 Metastatic breast cancer 62 imatinib resistant 62 K ras mutations 62 hyperbilirubinemia 62 DFMO 62 Seliciclib 62 chronic granulomatous disease 62 urothelial carcinoma 62 rheumatoid arthritis psoriatic arthritis 62 small lymphocytic lymphoma 62 Glioblastoma 62 taxane therapy 62 eosinophilic asthma 62 LHRH receptor positive 62 herpes zoster shingles 62 Hurler syndrome 62 prostate adenocarcinoma 62 lymphomas 62 recurrent NSCLC 62 Non Alcoholic Steatohepatitis 62 sarcomas 62 MAGE A3 ASCI 62 skeletal metastases 62 Xanafide 62 seminoma 62 Crohn disease CD 62 trans retinoic acid 62 systemic ALCL 62 SUVmax 62 chronic myeloid leukemia CML 62 Cholangiocarcinoma 62 Idiopathic Thrombocytopenic Purpura ITP 62 progressive neurodegenerative disorder 62 relapsed refractory AML 62 Brain metastases 62 invasive ductal 62 2 diabetes T2D 62 Aplidin 62 lymphocytic 62 cutaneous T 62 Tyrima 62 nutlin 3a 62 AGILECT R 62 anthracycline chemotherapy 62 Velcade bortezomib 62 relapsing multiple sclerosis 62 tumor histology 62 nonhereditary 62 castrate resistant 62 Papillary 62 Acute Myelogenous Leukemia AML 62 bleomycin 62 Renal cell carcinoma 62 ANCA associated 62 systemic amyloidosis 62 alkylating agent 62 pediatric neuroblastoma 62 esophageal adenocarcinoma 62 cediranib 62 rheumatologic 62 lysosomal storage disease 62 metastatic pancreatic 62 endometrial cancers 62 JAK mutations 62 Vidaza ® 62 recurrent metastatic 62 relapsing remitting MS RRMS 62 nonalcoholic steatohepatitis 62 dexpramipexole 62 lymphoid tumors 62 cutaneous squamous cell carcinoma 62 leiomyomas 62 benign prostatic hypertrophy BPH 62 locoregional recurrence 62 anti leukemic 62 Acute Lymphocytic Leukemia 62 follicular NHL 62 advanced adenoma 62 nonmelanoma 62 myelodysplasia 62 leukemia APL 62 invasive carcinoma 62 anaplastic 62 plasma kallikrein 62 autosomal recessive disease 62 pediatric malignancies 62 receptor inhibitor 62 grade glioma 62 RRMS patients 62 Nilotinib 62 CP CPPS 62 potentially hepatotoxic 62 imatinib resistance 62 #q# deletion syndrome 62 systemic juvenile idiopathic 62 bronchopulmonary dysplasia 62 relapsed acute myelogenous 62 Inflammatory bowel disease 62 Aflibercept 62 YONDELIS 62 pertuzumab 62 Venous thromboembolism 62 familial pancreatic cancer 62 premalignant 62 indolent follicular non 62 adenocarcinomas 62 papillary carcinoma 62 colorectal liver metastases 62 TMP SMX 62 PREZISTA r 62 TACE 62 mutated KRAS 62 myeloid leukemia 62 angiosarcoma 62 invasive fungal infection 62 hematological diseases 62 Multiple Myeloma MM 62 visilizumab 62 Teriflunomide 62 oesophageal adenocarcinoma 62 relapsed refractory multiple myeloma 62 bendamustine 62 Chronic Myeloid Leukemia 62 anaplastic astrocytoma 62 colorectal cancer CRC 62 Squamous 62 fatal neurodegenerative disorder 62 mycophenolate mofetil 62 remission induction 62 liver metastasis 62 Soft tissue sarcomas 62 unresectable stage 62 ductal breast cancer 61 leukoencephalopathy 61 topotecan 61 childhood leukemias 61 dasatinib Sprycel ® 61 Lymphocytic 61 immunocompetent 61 hypereosinophilic syndrome 61 nucleoside analogue 61 sporadic ALS 61 CHOP chemotherapy 61 standard chemotherapy regimen 61 glioblastoma tumors 61 precancerous cervical 61 diffuse intrinsic pontine glioma 61 Soft Tissue Sarcoma 61 ixabepilone 61 carcinoids 61 ovarian carcinoma 61 LHRH antagonists 61 IFN beta 61 xenograft models 61 peritoneal cancer 61 cutaneous melanoma 61 Chronic Lymphocytic Leukemia CLL 61 ALI ARDS 61 Acute Lymphoblastic Leukemia 61 depsipeptide 61 alemtuzumab treated 61 recurrent glioma 61 peritoneal carcinomatosis 61 proteasome inhibitor 61 B CLL 61 blastic phase 61 myeloproliferative diseases 61 Epratuzumab 61 refractory acute myeloid 61 squamous histology 61 Idiopathic pulmonary fibrosis 61 talabostat 61 trabectedin 61 stage IIIB IV 61 gastrointestinal cancers 61 cranial irradiation 61 radiochemotherapy 61 molecular abnormalities 61 breast carcinoma 61 euthymic patients 61 HNPCC 61 completely resected 61 temsirolimus 61 primitive neuroectodermal tumor 61 pulmonary metastasis 61 NNRTI resistance 61 gemcitabine Gemzar ® 61 Symadex 61 cholangiocarcinoma 61 serous ovarian cancer 61 V#F mutation 61 narcolepsy cataplexy 61 relapsed refractory 61 Inhaled nitric oxide 61 malignant fibrous histiocytoma 61 HSCT 61 pegylated liposomal doxorubicin 61 rALLy 61 AAT deficiency 61 Akt inhibitor 61 Epstein Barr virus EBV 61 EndoTAGTM 1 61 trastuzumab Herceptin ® 61 relapsed acute lymphoblastic 61 standard chemotherapy regimens 61 systemic anaplastic large 61 Eisenmenger syndrome 61 etiologic 61 nucleoside analogs 61 Temsirolimus 61 resectable pancreatic cancer 61 GRN# 61 diffuse gastric 61 bladder carcinoma 61 BCR ABL mutations 61 novel tubulin binding 61 octreotide LAR 61 medically inoperable 61 Gorlin syndrome 61 chronic hepatitis cirrhosis 61 lymphomas leukemias 61 T#I mutant 61 infantile onset 61 PAOD 61 chorioamnionitis 61 primary hyperparathyroidism 61 5-FU/LV 61 subependymal giant cell 61 childhood acute lymphoblastic 61 HGS# 61 AEG# 61 familial ALS 61 systemic fungal infections 61 chronic HBV 61 relapsed multiple myeloma 61 EGFR inhibitors 61 Pathway Inhibitor 61 proband 61 B Cell Lymphoma 61 Hashimoto thyroiditis 61 vesicoureteral reflux 61 methotrexate therapy 61 calcineurin inhibitors 61 relapsing remitting 61 generalized epilepsy 61 relapsed Acute Myeloid 61 epigenetic therapies 61 pancreatic carcinoma 61 anti angiogenic therapy 61 anterior uveitis 61 prostate cancer PCa 61 baseline LDH 61 follicular lymphoma 61 imatinib therapy 61 non hodgkin lymphoma 61 Radiofrequency ablation 61 acute coronary syndromes ACS 61 refractory chronic myeloid 61 AA Amyloidosis 61 T2DM 61 epithelial ovarian cancer 61 advanced metastatic renal 61 post transplant lymphoproliferative 61 Glioblastoma Multiforme GBM 61 cerebral vasospasm 61 hydroxymethyl coenzyme 61 BMPR2 61 ABCB1 61 testicular germ cell 61 BAY #-# 61 distant metastasis 61 Human papillomavirus 61 p# biomarker 61 chronic idiopathic 61 gemcitabine carboplatin 61 alvespimycin 61 refractory metastatic 61 oral Hycamtin 61 Janus kinase 61 non squamous NSCLC 61 Myelofibrosis 61 ZACTIMA 61 autoinflammatory diseases 61 DIPG 61 Relapsing remitting MS 61 Hodgkin lymphoma NHL 61 irinotecan chemotherapy 61 recurrent VTE 61 colorectal carcinoma 61 transaminase elevations 61 medulloblastoma malignant brain tumor 61 FLT3 mutations 61 Blinatumomab 61 Chronic Myelogenous Leukemia CML 61 bevacizumab Avastin ® 61 familial amyloidotic polyneuropathy FAP 61 anti mitotic 61 AKT inhibitor 61 laboratory abnormalities 61 tumors GIST 61 preoperative chemotherapy 61 protein kinase inhibitor 61 polycythemia vera essential thrombocythemia 61 PNP inhibitor 61 Amrubicin 61 CA4P 61 lupus erythematosus 61 Aortic stenosis 61 Tamibarotene 61 signal transduction inhibitors 61 Ribavirin causes 61 diabetic kidney 61 advanced hepatocellular carcinoma 61 medulloblastoma 61 Juvenile Idiopathic Arthritis 61 PTLD 61 IPAH 61 Chronic pancreatitis 61 AML acute myeloid 61 Letairis ambrisentan 61 sodium glucose cotransporter 61 debilitating autoimmune 61 Major depressive disorder 61 FluCAM arm 61 Sjögren syndrome 61 recurrent ovarian cancer 61 cervical lymph nodes 61 Li Fraumeni 61 Bayer HealthCare Onyx Pharmaceuticals 60 recurrent venous thromboembolism 60 protein kinase inhibitors 60 orally administered inhibitor 60 precursor lesions 60 ELACYT 60 peritumoral brain edema 60 neurofibromatosis type 60 antiangiogenic agent 60 herpesviruses 60 regorafenib 60 hypoparathyroidism 60 relapsed CLL 60 inhibits Akt activation 60 sorafenib tablets 60 hepatocellular cancer 60 mapatumumab 60 biochemical relapse 60 humanised monoclonal antibody 60 pancreatic prostate 60 anti angiogenic agents 60 EBV infection 60 chronic HBV infection 60 familial hypercholesterolemia 60 monoclonal gammopathy 60 daunorubicin 60 grade serous ovarian 60 intravenous bisphosphonates 60 anthracycline taxane 60 cytotoxic chemotherapy 60 bullous 60 toenail onychomycosis 60 lung adenocarcinomas 60 pituitary adenomas 60 familial hypercholesterolemia FH 60 GIST tumors 60 PROSTVAC VF 60 castrate resistant prostate cancer 60 invasive lobular 60 choriocarcinoma 60 diabetic nephropathy 60 chronic immune thrombocytopenic 60 demyelinating 60 samalizumab 60 NOMID 60 fungoides 60 PsA 60 Severe Combined Immunodeficiency 60 medulloblastoma tumors 60 relapsed AML 60 azacytidine 60 recurrent UTI 60 Testicular cancer 60 Gleevec imatinib mesylate 60 Thrombocytopenia 60 AML MDS 60 Systemic lupus erythematosus 60 leiomyosarcoma 60 systemic scleroderma 60 chronic eosinophilic leukemia 60 posaconazole 60 Idiopathic Pulmonary Fibrosis 60 Pseudomonas aeruginosa infections 60 BRAF V#E mutation 60 candidiasis 60 eosinophilic pneumonia 60 biologic DMARD 60 metastatic colon cancer 60 intra abdominal abscess 60 chemopreventive agent 60 Hsp# inhibition 60 FOLFIRI 60 CIN2 + 60 Candida infection 60 cardiotoxicity 60 dasatinib 60 International Prognostic Scoring 60 elevated triglyceride levels 60 ALT flares 60 Azedra 60 generalized seizures 60 gastrointestinal malignancies 60 Metastatic 60 adriamycin 60 mCRC patients 60 pharmacokinetic interactions 60 pleural mesothelioma 60 locoregional 60 demonstrated antitumor activity 60 Mantle Cell Lymphoma 60 JMML 60 pathophysiological effects 60 Nonalcoholic fatty liver 60 acromegalic patients 60 lymphoblastic lymphoma 60 metastatic RCC 60 CTAP# Capsules 60 antithrombotics 60 Niemann Pick disease 60 Myelodysplastic Syndrome 60 AGHD 60 neuro inflammatory 60 Thyroid nodules 60 Anthracycline 60 SPRYCEL ® 60 Lennox Gastaut syndrome 60 T#I [002] 60 proliferative retinopathy 60 clodronate 60 Acute myeloid leukemia AML 60 definite stent thrombosis 60 CD# mAb 60 Haptoglobin 60 membranous nephropathy 60 HER2 expression 60 Gastric cancer 60 cytoreduction 60 stage IIIb IV 60 LHON 60 NovoTTF 60 gastrointestinal stromal tumors GIST 60 resistant hormone refractory 60 stage IIIA 60 chronic HCV 60 antibody mediated 60 hypoxia inducible factor 60 thromboembolic disease 60 elevated LDH 60 chemoresistant 60 immunodeficiency 60 neoplasia 60 estramustine 60 APOPTONE 60 schizophrenia CIAS 60 VEGF inhibitors 60 resectable 60 dyslipidaemia 60 biochemical recurrence 60 IV NSCLC 60 prior chemotherapy regimens 60 postoperative delirium 60 C. trachomatis 60 rFVIIa 60 HGPIN 60 radiolabeled TM# 60 Non Hodgkins lymphoma 60 synovial sarcoma 60 Bortezomib 60 chemotherapeutic regimen 60 atherothrombotic disease 60 hormone refractory metastatic prostate 60 sarcomatoid 60 hepatitis C genotype 60 nucleoside analog 60 lung metastasis 60 bevacizumab Avastin 60 HER2 positive 60 platinum refractory 60 KRAS status 60 smoldering multiple myeloma 60 IMiDs ® compound 60 PEGylated interferon beta 1a 60 allogeneic bone marrow 60 Nexavar sorafenib 60 infliximab Remicade 60 nodal metastasis 60 pulmonary metastases 60 Pemetrexed 60 vinca alkaloids 60 PD LID 60 pamidronate 60 TGFBR1 * 6A 60 malignant neoplasms 60 C1 INH deficiency 60 dacarbazine 60 squamous cell cancers 60 BRAF V#E 60 CMV disease 60 Flu Cy 60 recurrent wheezing 60 atherothrombosis 60 lobular carcinoma 60 hormone deprivation 60 squamous 60 breast cancer subtypes 60 MCyR 60 Pleural mesothelioma 60 LRP5 60 highly selective endothelin 60 tumor recurrence 60 renal cell carcinoma 60 curative resection 60 hematologic cancers 60 pseudotumor cerebri 60 chronic lymphocytic 60 tuberous sclerosis TS 60 Heavy menstrual bleeding 60 glycated hemoglobin levels 60 androgen deprivation 60 Anthracyclines 60 DLBCL 60 Virulizin ® 60 prednisone prednisolone 60 Philadelphia Chromosome Positive 60 precursor acute lymphoblastic 60 tyrosine kinase inhibitors 60 FOLFOX chemotherapy 60 desmoplastic 60 seminomas 60 androgen independent 60 immune dysregulation 60 erlotinib Tarceva 60 TNF antagonist 60 fibrosarcoma 60 prognostic biomarker 60 azacitidine 60 BARACLUDE ® 60 leukemias lymphomas 60 FDG PET imaging 60 Wiskott Aldrich syndrome 60 refractory Hodgkin 60 pulmonary hypertension PH 60 Ceflatonin 60 ovarian carcinomas 60 recurrent DVT 60 TEAEs 60 sargramostim 60 Crizotinib 60 dopaminergic therapy 60 taxane refractory 60 Decitabine 60 erythropoietic 60 neoplastic lesions 60 pan HDAC inhibitor 60 evaluating tivozanib 60 curative therapy 60 Cloretazine R 60 elotuzumab 60 vidofludimus 60 forodesine 60 HCV infections 60 mg administered orally 60 hormone refractory 60 Bezielle 60 immunodeficiencies 60 carcinoid tumor 60 Evoltra ® 60 conventional DMARDs 60 Acute myelogenous leukemia 60 malignancies 60 DOXIL 60 Alzheimer Disease AD 60 pancreatic lung 60 Tarceva TM 60 HBeAg positive 60 oral squamous cell 60 castration resistant prostate cancer 60 biliary tract cancer 60 virological failure 60 hemodynamically significant 60 perioperative complications 60 crizotinib PF # 60 neurological manifestations 60 leukemias 60 genitourinary GU 60 chronic idiopathic thrombocytopenic purpura 60 Diabetic nephropathy 60 CTEPH 60 decompensated liver disease 60 Febrile neutropenia 60 Burkitt lymphoma 60 CIN3 60 FTLD 60 minimally symptomatic 60 fibromyalgia syndrome 60 antibody MAb 60 GH deficiency 60 low dose cytarabine 60 systemic sclerosis SSc 60 Subgroup analysis 60 germline mutations 60 gemcitabine Gemzar 60 urothelial bladder cancer 60 acne vulgaris 60 Adenocarcinoma 60 cervical lesions 60 Atypical antipsychotics 60 latent celiac disease 60 tumor xenograft models 60 Malignant Melanoma 60 cyclin E 60 IV metastatic melanoma 60 idraparinux 59 acute leukemia 59 keloid scarring 59 Clostridium difficile infections 59 chemotherapeutic drug 59 Herpes simplex virus 59 papillary thyroid cancer 59 relapsing remitting multiple sclerosis 59 Bronchiolitis 59 follicular thyroid cancer 59 Cell Lymphoma 59 Dasatinib 59 riociguat 59 urothelial cancer 59 abnormal p# 59 Familial Adenomatous Polyposis 59 thetreatment 59 embryonal rhabdomyosarcoma 59 vorinostat 59 thrombocytopenic 59 enzastaurin 59 cranial radiation 59 lymphoma CTCL 59 overt nephropathy 59 tamoxifen Nolvadex ® 59 cetuximab Erbitux R 59 biologic therapy 59 fatal neurodegenerative 59 untreated de novo 59 gastrointestinal perforation 59 EXJADE 59 Safinamide 59 atopic asthma 59 elevated LDL cholesterol 59 extracranial 59 cabazitaxel 59 APOL1 59 prostate cancer HRPC 59 potent antiproliferative 59 Lenocta 59 postoperative AF 59 uveal melanoma 59 myelodysplastic myeloproliferative diseases 59 inherited mutations 59 Adenomas 59 herpes simplex encephalitis 59 hepatic encephalopathy HE 59 antithrombotic therapy 59 common hematologic malignancy 59 interstitial lung disease 59 cell lymphoma ALCL 59 hematologic malignancies 59 EGFR HER2 59 Pancreatic neuroendocrine tumors 59 Pulmonary arterial hypertension 59 pouchitis 59 neutropenia dehydration dyspnea 59 Meningiomas 59 EOquin TM phase 59 NXL# 59 prognostic indicators 59 decitabine 59 alkylating 59 System IPSS 59 ErbB2 positive 59 Bcr Abl mutations 59 Non Hodgkin 59 gastric carcinogenesis 59 HER2 positive breast cancer 59 clinicopathological 59 EGFR blockers 59 chemotherapeutic regimens 59 GBA mutations